Myriad Genetics (MYGN) Change in Account Payables (2009 - 2026)

Myriad Genetics has disclosed Change in Account Payables across 18 years of filings, most recently posting $5.4 million for Q1 2026.

• In Q1 2026, Change in Account Payables changed N/A year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $4.0 million (up 385.71% YoY), while the FY2025 annual figure was -$1.4 million, down 129.79% from the prior year.
• Change in Account Payables improved to $5.4 million in Q1 2026, from -$4.2 million in the prior quarter.
• Over the last five years, Change in Account Payables for MYGN reached as high as $7.6 million in Q1 2023 and fell as low as -$8.5 million in Q3 2023.
• The 5-year median for Change in Account Payables is -$950000.0 (2024), against an average of $93750.0.
• Annual changes were most pronounced in 2022 — Change in Account Payables sank 1166.67% — and 2023, when it soared 337.5%.
• A 5-year view of Change in Account Payables shows it stood at -$2.4 million in 2022, then plunged by 145.83% to -$5.9 million in 2023, then surged by 81.36% to -$1.1 million in 2024, then slumped by 281.82% to -$4.2 million in 2025, then jumped by 228.57% to $5.4 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $5.4 million, -$4.2 million, and -$800000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.